Paysign (PAYS) Stock Overview

Provides prepaid card programs, patient affordability offerings, digital banking, life science software technology solutions, and integrated payment processing services for businesses, consumers, and government institutions in the United States. More details

PAYS fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	4/6
Past Performance	6/6
Financial Health	6/6
Dividends	0/6

Rewards

Earnings are forecast to grow 32.24% per year

Earnings grew by 132.5% over the past year

Risk Analysis

Volatile share price over the past 3 months compared to the US market

Significant insider selling over the past 3 months

PAYS Community Fair Values

Create Narrative

See what 40 others think this stock is worth. Follow their fair value or set your own to get alerts.

Plasma Decline And Fintech Risks Will Test Stability, Affordability Helps

Top Community Narratives

Paysign

J_Tyrader

Community Contributor

5/8/26 — Paysign: trading 79% below a 9.8%-discounted fair value, with the cash flow to defend it

Paysign looks cheap compared with what it’s already bringing in, backed by strong cash generation and a balance sheet with plenty of breathing room. The big question is whether today’s fast growth can last, especially with upcoming results and a possible mismatch between third‑party data and the company’s filings.

View narrative

US$43.01

71.0% undervalued

================================================================================ INTRINSIC VALUE (DCF) CALCULATION BREAKDOWN — NASDAQ:PAYS ================================================================================ Target Fair Value: USD 43.01 Current Stock Price: USD 9.17 Market Assessment: 78.7% Undervalued / +369.1% Upside Potential -------------------------------------------------------------------------------- 1. MARKET METRICS RECONCILIATION -------------------------------------------------------------------------------- * Undervaluation Formula: (Fair Value - Current Price) / Fair Value (43.01 - 9.17) / 43.01 = 0.7868 -> 78.7% * Upside Potential Formula: (Fair Value - Current Price) / Current Price (43.01 - 9.17) / 9.17 = 3.6906 -> +369.1% -------------------------------------------------------------------------------- 2. DISCOUNT RATE / COST OF EQUITY (CAPM) -------------------------------------------------------------------------------- * Formula: Risk-Free Rate + (Beta * Equity Risk Premium) * Inputs: Risk-Free Rate = 4.25% Beta = 1.10 ERP = 5.00% * Calculation: 4.25% + (1.10 * 5.00%) = 4.25% + 5.50% = 9.75% (Rounded to 9.8%) -------------------------------------------------------------------------------- 3. 10-YEAR CASH FLOW FORECAST ARCHITECTURE -------------------------------------------------------------------------------- * Base Year Free Cash Flow (FCF0): USD 70.02M (USD 1.2524 per share) * Shares Outstanding: 55.91m (Market Cap 512.66M / Price 9.17) * FCF Margin: 76.5% * Growth Rate Fading Schedule: - Year 1: +25.00% FCF USD 87.52M - Years 2-10: Linear reduction from +25.00% down to +2.50% - Year 10: +2.50% FCF USD 248.91M - Year 11+: +2.50% (Terminal Perpetual Growth Rate) -------------------------------------------------------------------------------- 4. MATHEMATICAL STEPS TO INTRINSIC VALUE -------------------------------------------------------------------------------- * Step A: Present Value of Discrete Cash Flows (Years 1 to 10) PV_Cash_Flows = Sum [ FCF_t / (1 + 0.0975)^t ] for t = 1 to 10 PV_Cash_Flows = USD 1.02B * Step B: Terminal Value (Gordon Growth Model at Year 10) TV_10 = [ FCF_10 * (1 + 0.0250) ] / (0.0975 - 0.0250) TV_10 = [ 248.91M * 1.0250 ] / 0.0725 = USD 3.52B * Step C: Discount the Terminal Value to Present Day PV_TV = 3.52B / (1 + 0.0975)^10 = 3.52B / 2.5354 PV_TV = USD 1.39B * Step D: Equity Value and Fair Value per Share Equity Value = 1.02B + 1.39B = USD 2.40B Fair Value = 2.40B / 55.91m = USD 43.01 -------------------------------------------------------------------------------- 5. FUTURE P/E MULTIPLE BLENDED BENCHMARK -------------------------------------------------------------------------------- * Formula: Sum of (Multiple * Re-normalized Weight) * Inputs: Forward Multiple: 39.9x @ 45% Weight Peer Median (n=13): 13.8x @ 35% Weight Current Multiple: 53.6x @ 20% Weight * Calculation: (39.9 * 0.45) + (13.8 * 0.35) + (53.6 * 0.20) = 17.941 + 4.817 + 10.719 = 33.477x (Rounded to 33.5x) -------------------------------------------------------------------------------- 6. SENSITIVITY OF THE FAIR VALUE -------------------------------------------------------------------------------- * Growth +22.0% -> 38.38 | +25.0% -> 43.01 | +28.0% -> 43.01 * Discount 8.75% -> 50.72 | 9.75% -> 43.01 | 10.75% -> 37.20 ================================================================================

Top Community Narratives

Paysign

J_Tyrader

Community Contributor

5/8/26 — Paysign: trading 79% below a 9.8%-discounted fair value, with the cash flow to defend it

View narrative

US$43.01

71.0% undervalued

Top Analyst Narratives

2.1% undervalued

AnalystHighTarget

1mo ago

Digital Payments And Healthcare Trends Will Drive Expansion

19.4% overvalued

AnalystConsensusTarget

3d ago

Digital Payment Solutions Will Expand Healthcare Access Further

Plasma Decline And Fintech Risks Will Test Stability, Affordability Helps

View all narratives

Paysign, Inc. Competitors

Priority Technology Holdings

NasdaqCM:PRTH

US$548.5m

International Money Express

NasdaqCM:IMXI

US$369.6m

Cass Information Systems

NasdaqGS:CASS

US$743.9m

Flywire

NasdaqGS:FLYW

US$2.2b

Price History & Performance

Summary of share price highs, lows and changes for Paysign
Historical stock prices
Current Share Price	US$12.48
52 Week High	US$12.85
52 Week Low	US$3.08
Beta	0.76
1 Month Change	42.14%
3 Month Change	100.64%
1 Year Change	122.46%
3 Year Change	514.78%
5 Year Change	369.17%
Change since IPO	2,673.33%

Recent News & Updates

New Narrative • Aug 05

5/8/26 — Paysign: trading 79% below a 9.8%-discounted fair value, with the cash flow to defend it

Paysign trades below the value implied by discounting its own free cash flow. On a two-stage model running 10 years of +25.0% growth fading to a 2.5% terminal rate, discounted at 9.8%, the shares are worth USD 43.01 against a market price of USD 9.17 — a 79% discount, or +369% to fair value.

Narrative Update • Aug 05

PAYS: Share Repurchase And New Pharma Programs Will Support Future Upside

Analysts raised their price target on Paysign to $11, up from a previous range of $8 to $9, citing the updated fair value estimate of $10.45 and the addition of new pharma programs as key factors supporting the change. What’s in the News for Paysign Paysign announced a share repurchase program that authorizes the company to buy back up to US$5 million of its outstanding common stock.

Narrative Update • Jun 24

PAYS: 2026 Earnings Guidance And Margin Outlook Will Support Repricing

Analysts have maintained their $12.75 price target on Paysign, citing updated assumptions for discount rate, revenue growth, profit margin and future P/E, which together support keeping the current valuation view unchanged. What’s in the News for Paysign Paysign issued earnings guidance for the second quarter of 2026, with expected revenue in a range of US$26.2 million to US$26.7 million.

Recent updates

New Narrative • Aug 05

5/8/26 — Paysign: trading 79% below a 9.8%-discounted fair value, with the cash flow to defend it

Narrative Update • Aug 05

PAYS: Share Repurchase And New Pharma Programs Will Support Future Upside

Narrative Update • Jun 24

PAYS: 2026 Earnings Guidance And Margin Outlook Will Support Repricing

Narrative Update • Jun 04

PAYS: Higher 2026 Margin Guidance And P/E Framework Will Support Repricing

Analysts have increased their price target on Paysign by $1 to $12.75, reflecting updated views on its growth, margins, and P/E assumptions. What's in the News Paysign issued earnings guidance for the first quarter of 2026, expecting revenue of US$27.0 million to US$27.5 million, with 137 active patient affordability programs and 589 plasma centers projected at quarter end.

Narrative Update • May 20

PAYS: Higher Margin Guidance And Premium P/E Framework Will Drive Repricing

Analysts have nudged their fair value estimate for Paysign up from $12.00 to $12.75, citing updated assumptions around growth, margins, and future P/E that fed into the latest price target increase highlighted in recent Street research. Analyst Commentary Recent Street research highlights a more constructive tone around Paysign, with bullish analysts pointing to the refreshed fair value estimate and updated assumptions as key supports for their views.

Narrative Update • Apr 30

PAYS: Higher Margin Outlook Will Support Repricing On Updated Profitability Assumptions

Analysts have raised their price target on Paysign by $1 to $12, citing updated assumptions around growth, profitability, discount rate and future P/E as the main drivers of this change. Analyst Commentary Bullish analysts are highlighting the recent price target move to US$12 as a sign of growing confidence in Paysign's outlook, with updated assumptions around growth, profitability, discount rate and future P/E at the core of their thesis.

Narrative Update • Apr 12

PAYS: Higher Margin Outlook And Raised P/E Assumption Will Support Repricing

Analysts lifted their Paysign price target by $1 to reflect slightly higher modeled revenue growth, modestly stronger profit margins, and an adjusted future P/E assumption, all under broadly consistent fair value and discount rate inputs. Analyst Commentary Bullish analysts framing the recent price target move highlight that the updated P/E assumption and slightly higher modeled revenue and margins support a higher fair value range for Paysign, while keeping discount rate inputs broadly consistent.

Narrative Update • Mar 28

PAYS: Higher Profit Margin Outlook Will Support More Constructive Share Repricing

The analyst price target for Paysign has increased from $9.50 to $12.00, with analysts citing updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E as key drivers of the change. Analyst Commentary Recent research points to a more constructive view on Paysign, with bullish analysts updating their models to reflect what they see as improved fair value assumptions and a more supportive outlook for key valuation inputs such as discount rate, revenue growth, profit margin and future P/E.

Analysis Article • Feb 05

The Price Is Right For Paysign, Inc. (NASDAQ:PAYS) Even After Diving 27%

Paysign, Inc. ( NASDAQ:PAYS ) shareholders that were waiting for something to happen have been dealt a blow with a 27...

Analysis Article • Nov 16

Paysign, Inc. Just Beat EPS By 100%: Here's What Analysts Think Will Happen Next

Paysign, Inc. ( NASDAQ:PAYS ) just released its quarterly report and things are looking bullish. The company beat...

Seeking Alpha • Oct 01

Paysign: Gaining Traction In The Patient Affordability Space Into 2026 (Hold)

Summary Paysign posted strong Q2 2025 results, with 33% YoY revenue growth and robust Pharma segment momentum, driven by US tariffs and new client wins. PAYS is rated a hold, as the stock trades at fair value ($5.83), despite expected high demand for co-payment cards and expanded patient affordability programs. Pharma segment revenue surged 189% YoY, offsetting a 4.7% YoY decline in the core Plasma segment, which faces ongoing headwinds from transitioning centers. While PAYS benefits from industry tailwinds and guidance consistency, risks remain due to Plasma's weakness and Pharma revenues still lagging Plasma's overall contribution. Read the full article on Seeking Alpha

Analysis Article • Aug 09

Paysign, Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

NasdaqCM:PAYS 1 Year Share Price vs Fair Value Explore Paysign's Fair Values from the Community and select yours One of...

Narrative Update • Aug 07

Digital Payment Solutions Will Expand Healthcare Access Further

Analysts maintain a positive outlook on Paysign due to ongoing growth in its Patient Affordability segment, confidence in its pharmaceutical pipeline, and scalable model, resulting in no change to the consensus price target, which remains at $9.10. Analyst Commentary Bullish analysts highlight a strong outlook for Paysign's Patient Affordability segment, especially within the pharmaceutical industry.

Analysis Article • May 06

Paysign, Inc.'s (NASDAQ:PAYS) 28% Price Boost Is Out Of Tune With Earnings

Those holding Paysign, Inc. ( NASDAQ:PAYS ) shares would be relieved that the share price has rebounded 28% in the last...

Analysis Article • Mar 04

Paysign, Inc.'s (NASDAQ:PAYS) Share Price Not Quite Adding Up

With a median price-to-earnings (or "P/E") ratio of close to 18x in the United States, you could be forgiven for...

Analysis Article • Dec 27

Here's Why Paysign (NASDAQ:PAYS) Has Caught The Eye Of Investors

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...

Seeking Alpha • Nov 20

Paysign Is A Leader In Fintech Healthcare Payments With Durable Profitable Growth

Summary Paysign is a promising microcap payment processing company with a projected 42% annualized return, potentially reaching $19/share by 2030 from $3.30/share today. The company excels in two primary sectors: plasma payment processing and pharma patient affordability, both offering significant growth and high gross margins. PAYS's plasma business boasts a 40% market share with steady 10-15% annual growth, while the pharma segment is expected to surpass plasma with rapid expansion. Risks include increased competition, potential loss of key customers, and limited financial resources, but catalysts like market share gains and acquisition potential bolster the investment thesis. Read the full article on Seeking Alpha

New Narrative • Sep 26

Rapid Growth In Patient Affordability Market Fuels Optimism Despite Looming Margin Pressures

The expansion into the patient affordability segment and significant client growth, like AstraZeneca, indicates a promising area for revenue and earnings increases.

Analysis Article • Sep 07

Do Paysign's (NASDAQ:PAYS) Earnings Warrant Your Attention?

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...

Analysis Article • Aug 02

Paysign, Inc. (NASDAQ:PAYS) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Paysign, Inc. ( NASDAQ:PAYS ) shareholders are probably feeling a little disappointed, since its shares fell 7.1% to...

Seeking Alpha • Jun 30

Paysign: Expect Rapid Growth In Its Pharma Business

Summary Shares have risen sharply this year, reflecting solid business performance. Its pharma segment is experiencing exceptional growth and has a long runway for continued expansion. My valuation model indicates that shares have limited upside. Read the full article on Seeking Alpha

Analysis Article • Apr 26

Paysign, Inc. (NASDAQ:PAYS) Stocks Shoot Up 30% But Its P/S Still Looks Reasonable

Paysign, Inc. ( NASDAQ:PAYS ) shares have continued their recent momentum with a 30% gain in the last month alone. The...

Analysis Article • Mar 29

Here's Why We Think PaySign (NASDAQ:PAYS) Is Well Worth Watching

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...

Analysis Article • Jan 25

Revenues Tell The Story For PaySign, Inc. (NASDAQ:PAYS)

PaySign, Inc.'s ( NASDAQ:PAYS ) price-to-sales (or "P/S") ratio of 3.4x may not look like an appealing investment...

Shareholder Returns

	PAYS	US Diversified Financial	US Market
7D	39.3%	0.5%	4.0%
1Y	122.5%	3.3%	20.7%

Return vs Industry: PAYS exceeded the US Diversified Financial industry which returned 3.3% over the past year.

Return vs Market: PAYS exceeded the US Market which returned 20.7% over the past year.

Price Volatility

Is PAYS's price volatile compared to industry and market?
PAYS volatility
PAYS Average Weekly Movement	11.3%
Diversified Financial Industry Average Movement	6.1%
Market Average Movement	7.2%
10% most volatile stocks in US Market	16.2%
10% least volatile stocks in US Market	3.1%

Stable Share Price: PAYS's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: PAYS's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
2001	226	Mark Newcomer	www.paysign.com

Paysign, Inc. provides prepaid card programs, patient affordability offerings, digital banking, life science software technology solutions, and integrated payment processing services for businesses, consumers, and government institutions in the United States. The company offers solutions for corporate rewards, prepaid gift cards, general-purpose reloadable debit cards, employee incentives, consumer rebates, donor compensation, clinical trials, healthcare reimbursement payments and pharmaceutical payment assistance, and demand deposit accounts accessible with a debit card and software solutions. It also operates a customer service center; and offers a communication suite, including mobile app, two-way SMS, text alerts, and cardholder web portal.

Paysign, Inc. Fundamentals Summary

How do Paysign's earnings and revenue compare to its market cap?
PAYS fundamental statistics
Market cap	US$704.40m
Earnings (TTM)	US$15.77m
Revenue (TTM)	US$100.64m

44.7x

P/E Ratio

7.0x

P/S Ratio

Is PAYS overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PAYS income statement (TTM)
Revenue	US$100.64m
Cost of Revenue	US$39.26m
Gross Profit	US$61.39m
Other Expenses	US$45.61m
Earnings	US$15.77m

Last Reported Earnings

Jun 30, 2026

Next Earnings Date

n/a

Earnings per share (EPS)	0.28
Gross Margin	61.00%
Net Profit Margin	15.67%
Debt/Equity Ratio	0%

How did PAYS perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/08/08 15:21
End of Day Share Price	2026/08/07 00:00
Earnings	2026/06/30
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Paysign, Inc. is covered by 6 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Gary Prestopino	Barrington Research Associates, Inc.
Austin Moldow	Canaccord Genuity
Peter Heckmann	D.A. Davidson & Co.

Paysign (PAYS) Stock Overview

Rewards

Risk Analysis

Analyst Price Targets

Digital Payments And Healthcare Trends Will Drive Expansion

Digital Payment Solutions Will Expand Healthcare Access Further

Plasma Decline And Fintech Risks Will Test Stability, Affordability Helps

Top Community Narratives

5/8/26 — Paysign: trading 79% below a 9.8%-discounted fair value, with the cash flow to defend it

Top Community Narratives

5/8/26 — Paysign: trading 79% below a 9.8%-discounted fair value, with the cash flow to defend it

Top Analyst Narratives

Digital Payments And Healthcare Trends Will Drive Expansion

Digital Payment Solutions Will Expand Healthcare Access Further

Plasma Decline And Fintech Risks Will Test Stability, Affordability Helps

Paysign, Inc. Competitors

Priority Technology Holdings

International Money Express

Cass Information Systems

Flywire

Price History & Performance

Recent News & Updates

New minor risk - Share price stability

Co-Founder exercised options and sold US$529k worth of stock

5/8/26 — Paysign: trading 79% below a 9.8%-discounted fair value, with the cash flow to defend it

PAYS: Share Repurchase And New Pharma Programs Will Support Future Upside

Paysign, Inc. to Report Q2, 2026 Results on Aug 05, 2026

PAYS: 2026 Earnings Guidance And Margin Outlook Will Support Repricing

Recent updates

New minor risk - Share price stability

Co-Founder exercised options and sold US$529k worth of stock

5/8/26 — Paysign: trading 79% below a 9.8%-discounted fair value, with the cash flow to defend it

PAYS: Share Repurchase And New Pharma Programs Will Support Future Upside

Paysign, Inc. to Report Q2, 2026 Results on Aug 05, 2026

PAYS: 2026 Earnings Guidance And Margin Outlook Will Support Repricing

PAYS: Higher 2026 Margin Guidance And P/E Framework Will Support Repricing

Investor sentiment improves as stock rises 20%

PAYS: Higher Margin Guidance And Premium P/E Framework Will Drive Repricing

Paysign, Inc. Provides Earnings Guidance for the Second Quarter 2026 and Reiterates Earnings Guidance for the Full-Year 2026

Paysign Q1 Revenue Surges 50.8% as Pharma Segment Becomes Top Driver

First quarter 2026 earnings: EPS and revenues exceed analyst expectations

PAYS: Higher Margin Outlook Will Support Repricing On Updated Profitability Assumptions

Investor sentiment improves as stock rises 20%

PAYS: Higher Margin Outlook And Raised P/E Assumption Will Support Repricing

Consensus revenue estimates increase by 10%

Consensus EPS estimates increase by 32%

PAYS: Higher Profit Margin Outlook Will Support More Constructive Share Repricing

Paysign, Inc., Annual General Meeting, May 08, 2026

Paysign, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2026

New minor risk - Share price stability

Full year 2025 earnings: EPS and revenues exceed analyst expectations

Investor sentiment deteriorates as stock falls 16%

The Price Is Right For Paysign, Inc. (NASDAQ:PAYS) Even After Diving 27%

Insufficient new directors

Consensus EPS estimates increase by 15%

Paysign, Inc. Just Beat EPS By 100%: Here's What Analysts Think Will Happen Next

Third quarter 2025 earnings: EPS and revenues exceed analyst expectations

Paysign, Inc. Updates Earnings Guidance for the Full Year 2025

Investor sentiment deteriorates as stock falls 16%

Paysign: Gaining Traction In The Patient Affordability Space Into 2026 (Hold)

Paysign, Inc. Appoints Jose Garcia as Executive Vice President, Life Science Solutions

Paysign, Inc. Announces Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions

Paysign, Inc. Announces Board Changes

Paysign, Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Digital Payment Solutions Will Expand Healthcare Access Further

Second quarter 2025 earnings released

Co-Founder exercised options and sold US$440k worth of stock

Paysign, Inc. Provides Earnings Guidance for the Third Quarter and Updates Earnings Guidance for Full Year 2025

Price target increased by 11% to US$8.40

Investor sentiment improves as stock rises 16%

Independent Director recently bought US$50k worth of stock

Price target increased by 7.5% to US$7.15

Non-Executive Independent Director exercised options to buy US$87k worth of stock.

New minor risk - Share price stability

Investor sentiment improves as stock rises 23%

Consensus EPS estimates have been upgraded.

Price target increased by 9.9% to US$6.65

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Paysign, Inc. Provides Earnings Guidance for the Second Quarter and Full Year 2025

Investor sentiment improves as stock rises 18%